![Blake Aftab](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 23 908 $ op 31-05-2026
Blake Aftab currently works at Adicet Bio, Inc., as Chief Scientific Officer & Senior Vice President from 2021.
Dr. Aftab also formerly worked at Atara Biotherapeutics, Inc., as Vice President & Head-Preclinical Science.
Dr. Aftab received his undergraduate degree from the University of California, Santa Barbara and doctorate degree from The Johns Hopkins University School of Medicine.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ADICET BIO INC 0,03% | 19-06-2026 | 2.568 ( 0,03% ) | 23 908 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ADICET BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 13-04-2021 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 4 |
|---|---|
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Adicet Bio, Inc.
 Adicet Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development of cell immunotherapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
Kies MarketScreener 
